Roche strikes $4.8B deal to acquire Spark Therapeutics

Drug giant Roche will buy gene therapy developer Spark Therapeutics for about $4.8 billion in cash, according to Bloomberg.

Roche will pay $114.50 per share, more than twice Spark's closing price on Feb. 22.

The deal will give Roche access to a gene therapy for blindness priced at $850,000 per patient, as well as other projects for hemophilia and neurodegenerative disorders like Huntington's disease.

Roche's deal comes as other big-name drugmakers pivot to gene therapy.

Read the full report here.

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars